Kibow Biotech, Inc. Launches Limited Human Clinical Trial in North America of Its Probiotic, Kibow Biotics, in Kidney Failure

PHILADELPHIA, July 16, 2007 (PRIME NEWSWIRE) -- Kibow Biotech announced today that it has initiated a limited, pilot-scale, double-blind, placebo-controlled, cross-over, six-month human clinical trial in North America of its probiotic formulation, Kibow Biotics(r) for slowing the progression of kidney failure

MORE ON THIS TOPIC